112 related articles for article (PubMed ID: 2553353)
21. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
[TBL] [Abstract][Full Text] [Related]
22. Hepatic resection for hepatocellular carcinoma existing with liver cirrhosis.
Ezaki T; Yamamoto K; Yamaguchi H; Sasaki Y; Ishida T; Mori M; Aimitsu S
Hepatogastroenterology; 2002; 49(47):1363-8. PubMed ID: 12239943
[TBL] [Abstract][Full Text] [Related]
23. Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver.
Noda S; Kawata S; Miyoshi S; Minami Y; Tarui S
Gastroenterol Jpn; 1989 Apr; 24(2):159-63. PubMed ID: 2545499
[TBL] [Abstract][Full Text] [Related]
24. Caffeine clearance study in hepatocellular carcinoma.
Tangkijvanich P; Wittayalertpanya S; Kusonsolboon T; Thong-Ngam D; Mahachai V
J Med Assoc Thai; 1999 Mar; 82(3):297-303. PubMed ID: 10410486
[TBL] [Abstract][Full Text] [Related]
25. [The value of studying liver function reserve in hepatic carcinoma by 13C-methacetin breath test].
Li HX; Wang JP; Yang Y; Zhang J; Feng QL
Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):383-7. PubMed ID: 19615155
[TBL] [Abstract][Full Text] [Related]
26. NX-DCP as a novel biomarker would be related to liver function in cirrhotic patients with hepatocellular carcinoma.
Hirano H; Saito M; Seo Y; Yano Y; Azuma T
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):748-9. PubMed ID: 23624798
[No Abstract] [Full Text] [Related]
27. The association between rifamycin-SV (R-SV) related hyperbilirubinaemia and antipyrine clearance as a new test of liver function in cirrhosis.
Persico M; Romano M; Villano N; Montella F; Gentile S
Eur J Clin Invest; 1994 Mar; 24(3):201-4. PubMed ID: 8033955
[TBL] [Abstract][Full Text] [Related]
28. [Changes in ketone body ratio and levels of pyruvate and lactate in arterial blood of patients with hepatocellular carcinoma after transcatheter arterial embolization].
Mizobuchi N; Kuwao F; Takeda I; Takemura T; Morita S; Horimi T; Takahashi I
Rinsho Byori; 1990 Jul; 38(7):825-9. PubMed ID: 2169547
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinomas do not compromise quantitative tests of liver function.
Ganslmayer M; Ocker M; Zopf S; Schuppan D; Hahn EG; Herold C
Hepatogastroenterology; 2005; 52(63):881-4. PubMed ID: 15966225
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
31. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
[TBL] [Abstract][Full Text] [Related]
32. [Antipyrine clearance in liver resections].
Fiorentini MT; Fracchia M; Biondi AM; Capussotti L; De La Pierre M; Molino G
Minerva Dietol Gastroenterol; 1990; 36(4):209-13. PubMed ID: 2089284
[TBL] [Abstract][Full Text] [Related]
33. Significance of hyperglobulinemia in severe chronic liver diseases--with special reference to the correlation between serum globulin/IgG level and ICG clearance.
Tanaka S; Okamoto Y; Yamazaki M; Mitani N; Nakqjima Y; Fukui H
Hepatogastroenterology; 2007 Dec; 54(80):2301-5. PubMed ID: 18265652
[TBL] [Abstract][Full Text] [Related]
34. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
von Mandach U; Jost G; Preisig R
Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
[TBL] [Abstract][Full Text] [Related]
35. Correlation between hepatic blood flow and coagulation indices in chronic active hepatitis and liver cirrhosis patients.
Violi F; Alessandri C; Saliola M; Caputo V; Bonavita MS; Balsano F
Haemostasis; 1985; 15(3):210-4. PubMed ID: 4029756
[TBL] [Abstract][Full Text] [Related]
36. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma.
Okubo M; Shiota G; Kawasaki H
Clin Sci (Lond); 2000 Sep; 99(3):207-14. PubMed ID: 11787473
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the redox tolerance index on hepatic energy reserve of hepatitis B patients.
Liu Z; Zhao L; Xu Z
Chin Med J (Engl); 1996 Feb; 109(2):147-50. PubMed ID: 8758341
[TBL] [Abstract][Full Text] [Related]
38. Alpha feto-protein and albumin in ascitic fluid in hepatocellular carcinoma patients.
Sadek A; Abdel Hady A; el Ayyat A; Hassan M; Mostafa I; Nouh A
J Egypt Soc Parasitol; 1997 Aug; 27(2):455-64. PubMed ID: 9257984
[TBL] [Abstract][Full Text] [Related]
39. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
40. Serum hepatocyte growth factor levels in liver diseases: clinical implications.
Shiota G; Okano J; Kawasaki H; Kawamoto T; Nakamura T
Hepatology; 1995 Jan; 21(1):106-12. PubMed ID: 7806142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
